PTC Therapeutics, Inc. Acquisitions, Net of Cash Acquired
PTC Therapeutics, Inc. (PTCT) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2021-02-25
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2019-12-31 was $0.00.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2018-12-31 was $0.00.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2018-09-30 was $48.89M.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for the quarter ending 2017-12-31 was $0.00.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2018 was $48.89M.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2017 was $0.00.
- PTC Therapeutics, Inc. payments to acquire businesses, net of cash acquired for fiscal 2016 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-10-30 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $48.89M derived: sum of 2 quarters · filed 2021-02-25 | $48.89M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $48.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $48.89M 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$76.42M derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | ||
| 2017-09-30 | -$76.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | $77.16M 10-Q · filed 2017-11-02 | ||
| 2017-06-30 | $76.42M 10-Q · filed 2018-08-07 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $0.00 10-Q · filed 2017-11-02 | |||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |